|
1
|
Batchelor T and Loeffler JS: Primary CNS
lymphoma. J Clin Oncol. 24:1281–1288. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abrey LE: Primary central nervous system
lymphoma. Curr Opin Neurol. 22:675–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Swerdlow SH, Campo E, Harris NL, et al:
World Health Organization Classification of tumours. Pathology and
genetics of tumours of haematopoietic and lymphoid tissuesWHO
press: WHO classification of tumours of haematopoietic and lymphoid
tissues. 4th. IARC; Lyon: pp. 236–237. 2008
|
|
4
|
Corn BW, Marcus SM, Topham A, Hauck W and
Curran WJ Jr: Will primary central nervous system lymphoma be the
most frequent brain tumor diagnosed in the year 2000? Cancer.
79:2409–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morris PG and Abrey LE: Therapeutic
challenges in primary CNS lymphoma. Lancet Neurol. 8:581–592. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nayak L and Batchelor TT: Recent advances
in treatment of primary central nervous system lymphoma. Curr Treat
Options Oncol. 14:539–552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pels H, Schmidt-Wolf IG, Glasmacher A,
Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H,
Kroschinsky F, et al: Primary central nervous system lymphoma:
Results of a pilot and phase II study of systemic and
intraventricular chemotherapy with deferred radiotherapy. J Clin
Oncol. 21:4489–4495. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abrey LE, Batchelor TT, Ferreri AJM,
Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A,
Soussain C, DeAngelis LM, et al: International Primary CNS Lymphoma
Collaborative Group: Report of an international workshop to
standardize baseline evaluation and response criteria for primary
CNS lymphoma. J Clin Oncol. 23:5034–5043. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reni M, Ferreri AJ, Garancini MP and Villa
E: Therapeutic management of primary central nervous system
lymphoma in immunocompetent patients: Results of a critical review
of the literature. Ann Oncol. 8:227–234. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cobert J, Hochberg E, Woldenberg N and
Hochberg F: Monotherapy with methotrexate for primary central
nervous lymphoma has single agent activity in the absence of
radiotherapy: a single institution cohort. J Neurooncol.
98:385–393. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferreri AJ, Reni M, Foppoli M, et al:
International Extranodal Lymphoma Study Group (IELSG): High-dose
cytarabine plus high-dose methotrexate versus high-dose
methotrexate alone in patients with primary CNS lymphoma: a
randomised phase 2 trial. Lancet. 374:1512–1520. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Poortmans PM, Kluin-Nelemans HC,
Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, Taphoorn M,
Thomas J, Van den Bent M, Fickers M, et al: European Organization
for Research and Treatment of Cancer Lymphoma Group: High-dose
methotrexate-based chemotherapy followed by consolidating
radiotherapy in non-AIDS-related primary central nervous system
lymphoma: European Organization for Research and Treatment of
Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol.
21:4483–4488. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferreri AJ, Dell'Oro S, Foppoli M,
Bernardi M, Brandes AA, Tosoni A, Montanari M, Balzarotti M, Spina
M, Ilariucci F, et al: MATILDE regimen followed by radiotherapy is
an active strategy against primary CNS lymphomas. Neurology.
66:1435–1438. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang XX, Huang HQ, Bai B, Cai QQ, Cai QC,
Gao Y, Xia YF, Xia ZJ and Jiang WQ: Clinical outcomes of patients
with newly diagnosed primary central nervous system lymphoma are
comparable on treatment with high-dose methotrexate plus
temozolomide and with high-dose methotrexate plus cytarabine: A
single-institution experience. Leuk Lymphoma. 55:2497–2501. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ferreri AJM, Reni M, Foppoli M, et al:
Randomized phase II trial on primary chemotherapy with high-dose
methotrexate alone or associated with highdose cytarabine for
patients with primary CNS lymphoma (IELSG #20 Trial): Tolerability,
activity and event-free survival analysis. Blood. 112:5802008.
|
|
16
|
Ferreri AJ, Reni M, Foppoli M, Martelli M,
Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G,
Ilariucci F, et al: International Extranodal Lymphoma Study Group
(IELSG): High-dose cytarabine plus high-dose methotrexate versus
high-dose methotrexate alone in patients with primary CNS lymphoma:
A randomised phase 2 trial. Lancet. 374:1512–1520. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feugier P, Virion JM, Tilly H, Haioun C,
Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, et
al: Incidence and risk factors for central nervous system
occurrence in elderly patients with diffuse large-B-cell lymphoma:
Influence of rituximab. Ann Oncol. 15:129–133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Holdhoff M, Ambady P, Abdelaziz A, Sarai
G, Bonekamp D, Blakeley J, Grossman SA and Ye X: High-dose
methotrexate with or without rituximab in newly diagnosed primary
CNS lymphoma. Neurology. 83:235–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Batchelor TT, Grossman SA, Mikkelsen T, Ye
X, Desideri S and Lesser GJ: Rituximab monotherapy for patients
with recurrent primary CNS lymphoma. Neurology. 76:929–930. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ghesquières H, Drouet Y, Sunyach MP,
Sebban C, Chassagne-Clement C, Jouanneau E, Honnorat J, Biron P and
Blay JY: Evidence of time-dependent prognostic factors predicting
early death but not long-term outcome in primary CNS lymphoma: A
study of 91 patients. Hematol Oncol. 31:57–64. 2013. View Article : Google Scholar
|
|
21
|
Liu BL, Cheng JX, Zhang X, Zhang W and
Cheng H: Limited role of surgery in the management of primary
central nervous system lymphoma (Review). Oncol Rep. 22:439–449.
2009.PubMed/NCBI
|
